Syngene International Limited

Syngene International has expanded its ongoing drug discovery and development operations with its US-based partner Bristol-Myers Squibb till 2026, the company said in a notice to the stock exchanges. The expansion would also include addition of a new facility and ramping up the team of scientists, the statement added. As part of the expansion, it will set up a new dedicated facility spread across 25,000 sq ft of laboratory and office space for Bristol-Myers Squibb. The stock of Syngene gained 1.4 per cent at ₹502.55 on the NSE.